Global Regulatory Harmonization in 2026: Aligning FDA, EMA, and PMDA for Complex Biologics

Pharmaceutical companies developing complex biologics face a regulatory landscape that is simultaneously converging and diverging. On one hand, the International Council for Harmonisation (ICH) continues to advance guidelines that create common ground across the world’s major regulatory agencies. On the other, the practical interpretation and implementation of those guidelines by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) remain distinct enough to create significant operational complexity for companies seeking multi-market approval.

In 2026, this tension between harmonization aspirations and regulatory reality is particularly acute for complex biologics, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, cell and gene therapies, and next-generation biosimilars. These products challenge the existing regulatory framework in ways that small-molecule drugs never did, and the three major agencies have each developed nuanced approaches that reflect their distinct regulatory philosophies, healthcare system priorities, and risk tolerance levels.

For regulatory affairs teams, quality operations leaders, and IT organizations supporting global submissions, understanding where harmonization has progressed, where gaps persist, and where new divergences are emerging is not an academic exercise. It directly shapes filing strategies, data management architectures, manufacturing documentation requirements, and the digital infrastructure needed to manage multi-market regulatory portfolios efficiently.

The Regulatory Harmonization Landscape in 2026

Global regulatory harmonization for pharmaceuticals has always been a work in progress rather than a destination. The concept gained institutional form with the establishment of the International Conference on Harmonisation (now the International Council for Harmonisation, or ICH) in 1990, bringing together regulatory authorities and industry representatives from Europe, Japan, and the United States to develop shared technical requirements for pharmaceutical registration.

Over the past three decades, ICH has produced more than sixty guidelines covering quality, safety, efficacy, and multidisciplinary topics. These guidelines have genuinely reduced the burden of preparing global submissions by establishing common expectations for stability testing, impurity standards, clinical trial design, pharmacovigilance, and many other areas. The Common Technical Document (CTD) format, codified in ICH M4, remains one of the most tangible achievements of harmonization, providing a standardized structure for regulatory submissions across ICH regions.

However, harmonization at the guideline level does not automatically translate to harmonization at the implementation level. Each agency retains sovereign authority over how it interprets and applies ICH guidelines, and each has supplemented the ICH framework with region-specific requirements, guidance documents, and regulatory practices that create meaningful differences in what sponsors must submit and demonstrate to gain marketing approval.

The ICH Framework and Its Evolving Role

The ICH framework for biologics regulation rests on several foundational guidelines that have been updated or are currently under revision to address the challenges posed by modern biologic products.

ICH Q5 series: The Q5 guidelines specifically address quality issues for biotechnological and biological products. ICH Q5A covers viral safety evaluation, Q5B addresses expression construct analysis, Q5C covers stability testing, Q5D addresses cell substrate characterization, and Q5E deals with comparability of biological products following manufacturing changes. Several of these guidelines are undergoing revision to reflect advances in analytical technology and manufacturing science.

ICH Q6B: This guideline establishes specifications for test procedures and acceptance criteria for biotechnological and biological products. Its application to increasingly complex molecules, including multispecific antibodies and antibody-drug conjugates, has required interpretive flexibility from regulators.

ICH Q8-Q12 modernization: The broader quality guidelines framework, encompassing pharmaceutical development (Q8), quality risk management (Q9), pharmaceutical quality system (Q10), development and manufacture of drug substances (Q11), and lifecycle management (Q12), continues to evolve. These guidelines collectively promote a science-based and risk-based approach to pharmaceutical quality that is particularly relevant for biologics, where process and product are tightly interlinked.

The ICH Assembly has also expanded its membership beyond the original founding regions to include regulatory authorities from additional countries, broadening the reach of harmonized standards but also introducing new perspectives and requirements into the consensus-building process. This expansion has slowed the pace of guideline development in some areas while making the resulting standards more globally applicable.

Why Complex Biologics Demand Greater Alignment

Complex biologics present regulatory challenges that fundamentally differ from those posed by traditional small-molecule drugs or even first-generation biologics. Understanding why harmonization matters more for these products requires appreciating the sources of complexity involved.

Molecular Complexity

Products such as bispecific antibodies, antibody-drug conjugates, and fusion proteins have structural complexity that exceeds what existing characterization guidelines were designed to address. A bispecific antibody, for example, must bind two distinct targets with appropriate affinity and specificity, and the manufacturing process must ensure consistent production of the intended molecular species while controlling for mispaired variants. When the three major agencies apply different analytical expectations to demonstrate structural consistency, sponsors must generate and present data in ways that satisfy multiple interpretive frameworks.

Manufacturing Process Sensitivity

For biologics, the product is fundamentally defined by the process used to make it. Cell line development, upstream fermentation or cell culture conditions, downstream purification sequences, and formulation parameters all influence the final product’s quality attributes. When agencies have different expectations for process validation, process characterization, or comparability assessment following manufacturing changes, the implications cascade through manufacturing strategy, facility design, and technology transfer planning.

Analytical Characterization Expectations

The suite of analytical methods used to characterize complex biologics, including mass spectrometry, chromatographic techniques, bioassays, and emerging methods like hydrogen-deuterium exchange, is constantly evolving. Agencies differ in their acceptance of novel analytical approaches, their expectations for method validation rigor, and their requirements for demonstrating that analytical methods are stability-indicating. These differences directly impact laboratory operations and data management strategies.

FDA’s Current Approach to Biologics Regulation

The FDA regulates most complex biologics through the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER), depending on the product type. The Biologics Price Competition and Innovation Act (BPCI Act) established the pathway for biosimilar and interchangeable biosimilar approval, and the agency has continued to refine its expectations for demonstrating biosimilarity through updated guidance documents.

Several recent developments characterize the FDA’s approach in 2026:

• Totality of evidence framework: The FDA evaluates biosimilarity claims based on the totality of evidence, including structural and functional characterization, animal studies (when warranted), and clinical pharmacology and clinical studies. The agency has moved toward allowing more abbreviated clinical programs when analytical similarity is particularly strong, reflecting growing confidence in modern characterization capabilities.
• Supplement classification for biosimilars: The FDA has finalized its approach to supplement classification for approved biosimilar products, clarifying how manufacturing changes and other post-approval modifications will be handled. This provides important predictability for lifecycle management of biosimilar products.
• Real-world evidence integration: The agency is increasingly open to incorporating real-world evidence into regulatory decision-making for biologics, particularly for post-marketing commitments and label expansion. This trend has implications for pharmacovigilance data systems and analytics infrastructure.
• Advanced manufacturing technologies: Through its Emerging Technology Program and related initiatives, the FDA is actively encouraging adoption of continuous manufacturing, process analytical technology, and other advanced manufacturing approaches for biologics. Companies that incorporate these technologies may benefit from more flexible regulatory engagement.

EMA’s Perspective on Biosimilar and Biologic Oversight

The European Medicines Agency has been at the forefront of biosimilar regulation since approving the first biosimilar in 2006, predating the FDA’s biosimilar pathway by several years. This longer experience has given the EMA a more mature framework for biosimilar evaluation, and European regulatory expectations continue to influence global standards.

The EMA’s approach to complex biologics in 2026 is characterized by several distinctive features:

• Product-specific biosimilar guidelines: The EMA maintains product-class-specific guidance for biosimilar development that provides detailed expectations tailored to the characteristics of each reference product category. These guidelines are more granular than the FDA’s general biosimilar guidance and can be more prescriptive about study design and endpoints.
• Scientific advice mechanism: The EMA’s scientific advice procedure provides a formal channel for sponsors to engage with the agency before and during development. The Committee for Medicinal Products for Human Use (CHMP) and its working parties offer substantive feedback that shapes development programs. This mechanism is well-established and widely used by companies developing complex biologics for the European market.
• Conditional marketing authorization: For products addressing unmet medical needs, the EMA’s conditional marketing authorization pathway allows earlier market access based on less complete data, with requirements for post-authorization studies. This pathway has been particularly relevant for advanced therapy medicinal products (ATMPs) and novel biologics.
• Quality-by-design emphasis: The EMA has been a strong proponent of quality-by-design principles for biologics manufacturing, and its expectations for process understanding and control strategy sophistication tend to align with or exceed ICH Q8-Q11 standards.

PMDA and the Japanese Regulatory Perspective

Japan’s Pharmaceuticals and Medical Devices Agency brings a regulatory perspective shaped by the country’s unique healthcare system, patient population characteristics, and pharmaceutical industry structure. The PMDA’s approach to biologics regulation has evolved significantly over the past decade, and understanding its current position is essential for companies planning global development programs.

The PMDA’s distinctive regulatory considerations include:

• Ethnicity-related bridging requirements: Japan has historically required bridging studies to demonstrate that data from non-Japanese populations are applicable to Japanese patients. For biologics, where pharmacokinetic and immunogenic responses may vary across ethnic groups, these requirements can add clinical development time and cost. While the agency has moved toward more flexible approaches, ethnicity-related considerations remain a planning factor.
• Regulatory science partnerships: The PMDA has invested in regulatory science initiatives that promote dialogue between the agency and industry on emerging scientific topics. These partnerships have been particularly productive in areas like biomarker qualification, companion diagnostics, and novel analytical methods for biologics.
• SAKIGAKE designation and AMED collaboration: Japan’s accelerated regulatory pathways for innovative products, including the SAKIGAKE designation system, provide expedited review for products offering significant therapeutic advantages. The agency’s collaboration with the Japan Agency for Medical Research and Development (AMED) supports regulatory science research that informs evaluation standards.
• Post-marketing surveillance emphasis: The PMDA places particular emphasis on post-marketing surveillance and pharmacovigilance, with requirements that can be more extensive than those in the United States or Europe. For biologics, where long-term immunogenicity and safety profiles are important, this emphasis translates into extended surveillance requirements and robust post-marketing data collection obligations.

Key Divergences Across the Three Agencies

Despite the substantial common ground created by ICH guidelines, several areas of significant regulatory divergence persist for complex biologics. These divergences have direct implications for development strategy, manufacturing planning, and regulatory submission preparation.

Biosimilar Approval Pathways and Classification Differences

The differences in how the three agencies handle biosimilar applications deserve particular attention, as biosimilars represent one of the fastest-growing segments of the biologics market and one of the areas where harmonization would deliver the greatest efficiency gains.

FDA: The BPCI Act Framework

The FDA’s biosimilar pathway under Section 351(k) of the Public Health Service Act requires demonstrating that the proposed product is highly similar to the reference product with no clinically meaningful differences. The agency has progressively clarified its expectations through a series of guidance documents covering quality considerations, clinical pharmacology data, and statistical approaches for demonstrating biosimilarity. Notably, the FDA has shown willingness to accept robust analytical evidence as the foundation for biosimilarity claims, potentially reducing the need for extensive clinical trials when characterization data are compelling.

The interchangeability designation, unique to the U.S. regulatory framework, imposes additional requirements including switching studies that demonstrate patients can alternate between the biosimilar and reference product without adverse effects. While relatively few products have achieved interchangeability designation to date, the concept remains a distinguishing feature of the U.S. system with significant commercial implications.

EMA: Pioneer Biosimilar Framework

The EMA’s biosimilar framework benefits from nearly two decades of experience and has evolved to incorporate lessons learned from the extensive European biosimilar market. The agency’s product-specific guidelines provide detailed development recommendations for each major product class, and the scientific advice mechanism allows sponsors to confirm their development approach before investing in potentially unnecessary studies.

A notable feature of the European system is the absence of a formal interchangeability determination at the EU level. Decisions about switching patients between reference products and biosimilars are made at the individual member state level, creating a patchwork of switching policies across Europe that sponsors and pharmacovigilance teams must track.

PMDA: Evolving Biosimilar Standards

Japan’s biosimilar market has grown more slowly than those in the United States and Europe, but the PMDA has been refining its regulatory expectations to support broader adoption. The agency’s approach maintains the expectation for clinical study data in most biosimilar applications, although the scope of required clinical programs has become more flexible as analytical capabilities have advanced. The bridging study paradigm adds a layer of complexity for global programs that must account for Japanese-specific data requirements.

Data Standards and Submission Format Harmonization

One of the areas where harmonization has made the most practical progress is in electronic submission standards, though important differences remain that complicate global regulatory information management.

The electronic Common Technical Document (eCTD) format, now in its version 4.0 iteration, provides a standardized structure for organizing and submitting regulatory information across all three ICH regions. The eCTD has dramatically reduced the effort required to prepare multi-market submissions compared to the era of paper-based or region-specific electronic formats. However, implementation differences persist.

Each agency maintains its own electronic gateway for receiving submissions, with distinct technical specifications, validation rules, and processing expectations. The FDA’s Electronic Submissions Gateway (ESG), the EMA’s Common European Submission Portal (CESP), and the PMDA’s Gateway system each have specific requirements that regulatory information management systems must accommodate.

Beyond the submission container format, data standards for the content within submissions are also converging through initiatives like the CDISC (Clinical Data Interchange Standards Consortium) standards for clinical trial data and the FDA’s structured product labeling (SPL) format. However, the pace and scope of adoption varies across regions, and companies must maintain the capability to produce data in multiple formats depending on the target market.

IDMP and Regulatory Data Standards

The ISO IDMP (Identification of Medicinal Products) standards represent a longer-term harmonization initiative that aims to create globally consistent terminology and data structures for describing medicinal products, their ingredients, and their regulatory status. The EMA has been the most aggressive in implementing IDMP through its SPOR (Substances, Products, Organizations, Referentials) master data management system, while the FDA and PMDA have progressed more slowly. Full IDMP implementation would significantly improve the ability to exchange regulatory information across agencies, but the timeline for global adoption remains extended.

Digital Infrastructure Implications for Multi-Market Filings

The state of regulatory harmonization, and its persistent gaps, has direct implications for the digital infrastructure that pharmaceutical companies need to manage global regulatory portfolios for complex biologics. IT leaders and digital transformation teams should consider several key areas when evaluating their organization’s readiness.

Regulatory Information Management Systems

Organizations managing multi-market biologics submissions need regulatory information management systems (RIMS) capable of tracking submission requirements, timelines, and content across jurisdictions. The system must accommodate the fact that the same product may face different data requirements, submission formats, and review timelines in different markets. Leading RIMS platforms provide multi-regional tracking capabilities, but effective configuration requires deep regulatory knowledge and ongoing maintenance as agency requirements evolve.

Document Management and Content Reuse

A significant portion of the content in regulatory submissions, particularly the quality (Module 3) and nonclinical (Module 4) sections, is common across markets. Effective document management strategies that maximize content reuse while accommodating region-specific requirements can dramatically reduce the effort and cost of multi-market submissions. This requires structured authoring approaches, granular content management, and robust version control that tracks which content versions have been submitted to which agencies.

Clinical Data Management and Standards Compliance

Clinical data collected for global registration programs must be managed in ways that satisfy multiple agency expectations for data standards, formats, and submission specifications. Investment in CDISC-compliant data management processes and systems is increasingly a baseline requirement, but organizations must also maintain awareness of agency-specific data requirements that go beyond CDISC standards.

Practical Strategies for Regulatory Operations Teams

Managing the complexity of multi-market regulatory filings for complex biologics requires deliberate strategy and disciplined execution. The following approaches have proven effective for organizations navigating the current harmonization landscape.

Invest in Early Regulatory Intelligence

Before committing to a global development strategy, invest in comprehensive regulatory intelligence that maps the specific requirements of each target market for your product type. This mapping should go beyond general awareness of agency differences to identify the specific data packages, study designs, and documentation requirements that will apply to your product. Engage with each agency’s formal advice mechanisms (FDA Pre-IND meetings, EMA scientific advice, PMDA consultations) to validate your understanding before making irreversible development decisions.

Design Global-First Development Programs

Development programs designed to satisfy the most stringent requirements across all target markets from the outset are more efficient than programs that retrofit data packages for secondary markets after the fact. This requires regulatory strategy input during early development planning, not just at the filing stage. For complex biologics, the analytical characterization program is often the area where a global-first design delivers the greatest efficiency gains, as comprehensive characterization data can support regulatory arguments across all three agencies.

Establish a Harmonization Monitoring Function

Regulatory harmonization is a dynamic process. New ICH guidelines, agency-specific guidance revisions, and shifts in regulatory practice can create both new opportunities for efficiency and new compliance obligations. Organizations should establish a formal monitoring function that tracks harmonization developments and translates them into actionable updates for development, manufacturing, and submission teams.

Build Flexible Submission Infrastructure

The regulatory information management and document publishing infrastructure must be flexible enough to accommodate both the common elements of multi-market submissions and the region-specific variations. Over-customization for any single market creates rigidity that increases the cost and effort of addressing other markets. Modular approaches to content management, with clear separation between core content and region-specific adaptations, provide the best balance of efficiency and compliance.

Leverage Mutual Recognition and Reliance Pathways

Increasingly, regulatory agencies are developing mutual recognition and reliance mechanisms that allow them to leverage assessments conducted by other agencies. While these mechanisms are more developed for some product categories than for complex biologics, they represent a growing opportunity to reduce duplicative regulatory work. Organizations should monitor the development of these pathways and factor them into long-term regulatory strategy.

Harmonize Internal Quality Standards

Organizations manufacturing complex biologics for global markets should establish internal quality standards that meet or exceed the most stringent requirements across all target markets. Operating to a single high standard is typically more efficient than maintaining market-specific quality tiers, and it positions the organization well for regulatory harmonization trends that are likely to push all agencies toward higher and more consistent expectations over time.

The trajectory of global regulatory harmonization for complex biologics is clearly toward greater alignment, but the pace of convergence varies across different aspects of the regulatory framework. Organizations that build their development strategies, digital infrastructure, and operational processes around the current reality of partial harmonization, while positioning themselves to benefit from future convergence, will navigate the landscape most effectively.

At Sakara Digital, we help pharmaceutical and life sciences organizations design regulatory information management architectures, implement multi-market submission infrastructure, and build the digital capabilities needed to manage complex global regulatory portfolios. If your organization is preparing for multi-market biologics filings, contact our team to discuss how we can support your regulatory operations strategy.